Rejuvenate Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Crowdfunding
  • (Announced)

  • Latest Deal Amount
  • $10.5M

  • Investors
  • 20

Rejuvenate Bio General Information

Description

Developer of gene therapies designed for treating chronic age-related diseases. The company's technology utilizes epigenetic reprogramming and bicistronic gene expression systems, enabling healthcare providers to treat metabolic diseases, cardiovascular conditions, kidney failure, osteoarthritis, and canine heart diseases.

Contact Information

Website
www.rejuvenatebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11425 Sorrento Valley Road
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 11425 Sorrento Valley Road
  • San Diego, CA 92121
  • United States
+1 (858)

Rejuvenate Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rejuvenate Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Equity Crowdfunding 22-Jan-2026 $10.5M Announced Clinical Trials - General
12. Later Stage VC (Series C) 20-Aug-2026 Completed Generating Revenue
11. Later Stage VC (Series B) 18-Jun-2026 Completed Clinical Trials - General
10. Secondary Transaction - Private Completed Clinical Trials - General
9. Grant 01-Jul-2024 Completed Clinical Trials - General
8. Accelerator/Incubator Completed Startup
7. Debt - General 28-May-2021 Completed Startup
6. Early Stage VC (Series A) 27-Apr-2021 Completed Startup
5. Grant 01-Jan-2020 $11M $2.2M Completed Startup
4. Seed Round 01-Jun-2018 $2.2M $2.2M Completed Startup
To view Rejuvenate Bio’s complete valuation and funding history, request access »

Rejuvenate Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series B-2
Series B-1
Series A-2
Series A-1 1,050,083 $0.000100 10% $0.85 $0.85 1x $0.85 1.33%
Series A 7,761,771 $0.000100 10% $1.74 $1.74 1x $1.74 9.81%
To view Rejuvenate Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Rejuvenate Bio Patents

  • 27

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 18

    Pending

  • Expiring in next 12 mo

Rejuvenate Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025376713-A1 Bicistronic gene expression systems and methods of use Pending 14-May-2024
WO-2025240607-A2 Bicistronic gene expression systems and methods of use Pending 14-May-2024
WO-2025240607-A3 Bicistronic gene expression systems and methods of use Pending 14-May-2024
WO-2025240607-A8 Bicistronic gene expression systems and methods of use Pending 14-May-2024
AU-2025376568-A1 Fgf21 gene therapy and methods therefor Pending 14-May-2024
To view Rejuvenate Bio’s complete patent history, request access »

Rejuvenate Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rejuvenate Bio Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gaingels Venture Capital Minority
Hyperspeed Ventures Venture Capital Minority
Jetstream Venture Fund Venture Capital Minority
Kingscrowd VC-Backed Company Minority
Connecticut Innovations Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial

Rejuvenate Bio FAQs

  • When was Rejuvenate Bio founded?

    Rejuvenate Bio was founded in 2017.

  • Where is Rejuvenate Bio headquartered?

    Rejuvenate Bio is headquartered in San Diego, CA.

  • What is the size of Rejuvenate Bio?

    Rejuvenate Bio has 16 total employees.

  • What industry is Rejuvenate Bio in?

    Rejuvenate Bio’s primary industry is Drug Discovery.

  • Is Rejuvenate Bio a private or public company?

    Rejuvenate Bio is a Private company.

  • What is the current valuation of Rejuvenate Bio?

    The current valuation of Rejuvenate Bio is .

  • What is Rejuvenate Bio’s current revenue?

    The current revenue for Rejuvenate Bio is .

  • How much funding has Rejuvenate Bio raised over time?

    Rejuvenate Bio has raised $39.3M.

  • Who are Rejuvenate Bio’s investors?

    Gaingels, Hyperspeed Ventures, Jetstream Venture Fund, Kingscrowd, and Connecticut Innovations are 5 of 20 investors who have invested in Rejuvenate Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process